[go: up one dir, main page]

WO1994004565A3 - Ipnv vaccine - Google Patents

Ipnv vaccine Download PDF

Info

Publication number
WO1994004565A3
WO1994004565A3 PCT/GB1993/001812 GB9301812W WO9404565A3 WO 1994004565 A3 WO1994004565 A3 WO 1994004565A3 GB 9301812 W GB9301812 W GB 9301812W WO 9404565 A3 WO9404565 A3 WO 9404565A3
Authority
WO
WIPO (PCT)
Prior art keywords
ser
gly
thr
pro
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1993/001812
Other languages
French (fr)
Other versions
WO1994004565A2 (en
Inventor
Robert Vincent Fishleigh
Paul John Greaney
Barry Robson
Ann Patricia Shakespeare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROTEUS HOUSE
Original Assignee
PROTEUS HOUSE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929218163A external-priority patent/GB9218163D0/en
Priority claimed from GB929219710A external-priority patent/GB9219710D0/en
Application filed by PROTEUS HOUSE filed Critical PROTEUS HOUSE
Priority to AU49701/93A priority Critical patent/AU4970193A/en
Publication of WO1994004565A2 publication Critical patent/WO1994004565A2/en
Publication of WO1994004565A3 publication Critical patent/WO1994004565A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides a synthetic polypeptide having at least one antigenic property of at least one strain of infectious pancreatic necrosis virus, said polypeptide consisting substantially of an amino acid sequence selected from formulae (I) to (IX): formula (I) (which contains Seq. ID No: 1) X-Thr-Thr-Asn-Pro-Gln-Asp-Lys-Val-Asn-Asn-Gln-Y; formula (II) (which contains Seq. ID Nos: 2 or 3) X-Thr-Asp-Phe-R1-Ser-Asp-Leu-Pro-Thr-Ser-Lys-Ala-Trp-Gly-Y; formula (III) (which contains Seq. ID No: 4) X-Pro-Thr-Ser-Lys-Ala-Trp-Gly-Trp-Arg-Asp-Y;fFormula (IV) (which contains Seq. ID No: 5) X-Thr-Lys-Tyr-Gly-Lys-Tyr-Asp-Pro-Glu-Gly-Y; formula (V) (which contains Seq. ID No: 6) X-Leu-Glu-Val-Ser-Glu-Ser-Gly-Ser-Gly-Y; formula (VI) (which contains Seq. ID Nos: 7 or 8) X-Gln-Glu-Thr-Ser-Ser-Tyr-R2-Leu-Glu-Val-Ser-Glu-Ser-Gly-Y; formula (VII) (which contains Seq. ID Nos: 9 or 10) X-Ser-Arg-Phe-Thr-Pro-Ser-Gly-Asp-R3-Y; and formula (VIII) (which contains Seq. ID Nos: 11 or 12) X-Pro-His-Gln-Glu-Pro-Ala-Pro-R4-Phe-Tyr-Y; formula (IX) (which contains Seq. ID Nos: 13, 14, 15 or 16) X-Pro-Gln-Gly-R5-Gln-Ser-Met-Asn-Gly-Ala-R6-Y, wherein R1 is Ser or Thr; R2 is Thr or Asn; R3 is Asp-Gly or Asn-Ala; R4 is Asp-Asp or Glu-Glu-; R5 is Pro or Leu; R6 is Arg or Lys; and X and Y may each independently be absent or independently be one or more amino acid residues, useful for the treatment of IPNV infection in fish.
PCT/GB1993/001812 1992-08-26 1993-08-25 Ipnv vaccine Ceased WO1994004565A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49701/93A AU4970193A (en) 1992-08-26 1993-08-25 IPNV vaccine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929218163A GB9218163D0 (en) 1992-08-26 1992-08-26 Synthetic polypeptides
GB9218163.5 1992-08-26
GB9219710.2 1992-09-17
GB929219710A GB9219710D0 (en) 1992-09-17 1992-09-17 Synthetic polypeptides

Publications (2)

Publication Number Publication Date
WO1994004565A2 WO1994004565A2 (en) 1994-03-03
WO1994004565A3 true WO1994004565A3 (en) 1994-06-09

Family

ID=26301496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001812 Ceased WO1994004565A2 (en) 1992-08-26 1993-08-25 Ipnv vaccine

Country Status (3)

Country Link
CN (1) CN1090584A (en)
AU (1) AU4970193A (en)
WO (1) WO1994004565A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005311A1 (en) * 1992-08-27 1994-03-17 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
TW201139672A (en) * 2002-12-13 2011-11-16 Novartis Ag Immunization of fish with plant-expressed recombinant proteins
GB201400311D0 (en) * 2014-01-08 2014-02-26 Aqua Gen As Treating Susceptibility
CA2954876A1 (en) * 2014-07-11 2016-01-14 Fundacion Fraunhofer Chile Research Agent with antiviral properties for preventing or treating individuals exposed to a virus of the birnaviridae family

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003570A1 (en) * 1989-09-04 1991-03-21 Sapporo Breweries Limited Monoclonal antibody against infectious pancreatic nephrosis virus having neutralizing activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003570A1 (en) * 1989-09-04 1991-03-21 Sapporo Breweries Limited Monoclonal antibody against infectious pancreatic nephrosis virus having neutralizing activity

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BAIOSAIENSU TO INDASUTORI, vol. 48, no. 10, 1990, pages 980 - 981 *
BAMFORD, J.K. ET AL.: "Genome organization of membrane-containing bacteriophage PRD1", VIROLOGY, vol. 183, 1991, pages 658 - 676, XP023059910, DOI: doi:10.1016/0042-6822(91)90995-N *
BIOLOGICAL ABSTRACTS, vol. 85, 1988, Philadelphia, PA, US; abstract no. 22948, AZAD, A.A. ET AL.: "Deletion mapping and expression in E. coli of the large genomic segment of a birnavirus" *
CASWELL-RENO, P. ET AL.: "Monoclonal antibodies to infectious pancreatic necrosis virus: Analysis of viral epitopes and comparison of different isolates", J. GEN. VIROL., vol. 67, 1986, pages 2193 - 2205 *
CHEMICAL ABSTRACTS, vol. 114, no. 5, 1991, Columbus, Ohio, US; abstract no. 40514, KAMEI, Y. & MURAKAMI, H.: "Production and application of monoclonal antibodies specific for fish viruses" page 40511; *
CHEMICAL ABSTRACTS, vol. 115, no. 15, 1991, Columbus, Ohio, US; abstract no. 156646, CHI, S.C. ET AL.: "Establishment, characterization, and application of monoclonal antibodies against eel virus European" page 712; *
DUNCAN, R. ET AL.: "Synthesis of the infectious pancreatic necrosis virus polyprotein ...", J. VIROL., vol. 61, no. 12, 1987, pages 3655 - 3664 *
DUVE, H. ET AL.: "Isolation, structure, and activity of -Phe-Met-Arg-Phe-NH2 neuropeptides ...", PROC. NATL. ACAD. SCI. USA, vol. 89, March 1992 (1992-03-01), pages 2326 - 2330 *
GYOBYO KENKYU, vol. 26, no. 1, 1991, pages 1 - 7 *
HAAVARSTEIN, L.S. ET AL.: "Sequence of the large double stranded RNA segment of the N1 strain of infectious pancreatic necrosis virus: a comparison with other Birnaviridae", J. GEN. VIROL., vol. 71, no. 2, 1990, pages 299 - 308, XP001062695 *
VIROLOGY, vol. 161, no. 1, 1987, pages 145-152 *
WIPKE, B.T. ET AL.: "Variable binding affinities of listeriolysin O peptides for the H-2Kd class I molecule", EUR. J. IMMUNOL., vol. 23, no. 8, August 1993 (1993-08-01), pages 2005 - 2010 *

Also Published As

Publication number Publication date
AU4970193A (en) 1994-03-15
CN1090584A (en) 1994-08-10
WO1994004565A2 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
AU1232602A (en) Vaccine composition
DE69432475D1 (en) OF HUMAN T CELLS IMMUNODOMINANT EPIROPEN OF THE VIRUS DER C-HEPATITIS
EP0528312A3 (en) Cyclic peptides and use thereof
CA2116764A1 (en) Immunoreactive Hepatitis C Virus Polypeptide Compositions
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
ATE154363T1 (en) SYNTHETIC POLYPEPTIDES AS INHIBITORS OF HIV-1
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
NO921829L (en) NEW POLYPEPTID, AND ANTI-HIV MEDICINE PREPARED THEREOF
SG63621A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
EP1501936A4 (en) Cytokine protein family
EP1006126A3 (en) Osteogenic peptides
AU671989B2 (en) Treatment of tropical spastic paresis with peptide T
WO1994004565A3 (en) Ipnv vaccine
ATE166068T1 (en) POLYPEPTIDES DERIVED FROM THE ENDONUCLEASE PROTEIN OF THE HUMAN IMMUNODEFICIENCY VIRUS
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
ATE116336T1 (en) BACTERIOCIN PEPTIDE.
EP0953642A4 (en) ANTIGEN PROTEIN FROM INFECTIOUS LARYNGOTRACHEITIS VIRUS
RU95118291A (en) COMPOSITIONS CONTAINING AN IMMUNOGENOUS PEPTIDE AND PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA